MDCX

Business Context and Reporting Period

Company: Medicus Pharma Ltd. (MDCX)
Filing Type: Form 8-K Current Report
Date of Report: July 14, 2025
Reporting Period: Events occurring on July 9, 2025, and July 14, 2025.
Business Overview: Medicus Pharma is an emerging growth company focused on clinical development, currently advancing the SKNJCT-003 exploratory trial and pursuing the acquisition of Antev Limited.

Key Financial Metrics and Capital Activities

This filing details specific capital raising activities rather than periodic financial performance metrics (e.g., revenue, net income, or operating cash flow are not reported in this 8-K).

• Warrant Inducement Proceeds: Expected gross proceeds of approximately $3.75 million from the exercise of 1,340,000 existing warrants at $2.80 per share.
• SEPA Advances Proceeds: Aggregate net proceeds of approximately $1.521 million from the sale of 490,000 common shares to Yorkville (YA II PN, Ltd.).
• Transaction Fees: A cash fee of 6.0% of gross proceeds from the warrant inducement is payable to Maxim Group, LLC.
• Debt Repayment: Part of the SEPA proceeds is intended to prepay outstanding debentures held by Yorkville.

Material Changes and Transactions

The filing reports two primary material events:

1. Warrant Inducement Agreement: The Company entered into an agreement with an institutional holder to exercise existing warrants. In exchange, the holder received new unregistered warrants to purchase up to 2,680,000 common shares (2x the number of shares underlying the exercised warrants).
   • New Warrant Terms: Exercise price of $3.75 per share; 5-year term.
   • Call Feature: One series of new warrants includes a provision allowing the Company to force exercise if the 10-day VWAP of common shares exceeds $10.00.
2. SEPA Share Sales: Under a Standby Equity Purchase Agreement, the Company sold shares to Yorkville in two tranches:
   • July 9, 2025: 155,000 shares at ~$3.2841/share (~$509,000).
   • July 14, 2025: 335,000 shares at ~$3.0216/share (~$1,012,000).

Guidance, Outlook, and Risks

Use of Proceeds: Net proceeds from both the warrant inducement and SEPA advances are designated for ongoing clinical trials, working capital, general corporate purposes, and costs associated with the acquisition of Antev Limited.

Management Commentary and Outlook:

• The Company aims to fast-track clinical development and convert the SKNJCT-003 exploratory trial into a pivotal trial.
• Plans include the commencement of the SKNJCT-004 study and potential FDA approval.
• The Company intends to file a Form S-1 registration statement for the resale of New Warrant Shares within 120 days of the agreement.

Risks and Contingencies:

• Forward-Looking Statements: The filing contains numerous forward-looking statements regarding clinical trial results, FDA approval timing, and the Antev transaction, which are subject to significant risks and uncertainties.
• Registration Risk: The New Warrants and New Warrant Shares are unregistered and cannot be sold in the U.S. absent registration or an exemption.
• Market Conditions: Actual results may differ materially from expectations due to economic conditions and regulatory outcomes.

Investor Verification Checklist

• Verify the closing of the Warrant Inducement Agreement and the actual receipt of the ~$3.75 million gross proceeds.
• Confirm the filing and effectiveness of the Form S-1 registration statement for the New Warrant Shares within the stipulated 120-day window.
• Monitor the status of the Antev Limited acquisition and the allocation of proceeds toward this transaction.
• Review the impact of the new warrant issuance (2,680,000 shares) on potential future dilution, particularly if the $10.00 VWAP call feature is triggered.
• Check subsequent filings for updates on the SKNJCT-003 and SKNJCT-004 clinical trial progress and FDA interactions.